Orum Therapeutics (475830) stock
KOSDAQ · Pharmaceuticals
As of Nov 16, 9:24 AM KST
- Market cap
- KRW 320.4 billion
- As of Nov 16, 2026
- P/E
- 17.31x
- Trailing twelve months
- P/B
- 1.72x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- 10.0%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 320.4 billion
- As of Nov 16, 2026
- P/E
- 17.31x
- Trailing twelve months
- P/B
- 1.72x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- 10.0%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
17.31x
P/B
1.72x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
KRW 851
Earnings per share
BPS
KRW 8,551
Book value per share
ROE
10.0%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 851 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 8,551 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 10.0%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| H1 2026Consolidated · Filed Aug 14, 2026 | KRW 0 | -KRW 33.4 billion | KRW 48.1 billion | +244.4% |
| Q1 2026Consolidated · Filed May 15, 2026 | — | -KRW 18.1 billion | -KRW 15.3 billion | — |
| Q4 2025Consolidated · Filed Mar 19, 2026 | KRW 0 | -KRW 18.3 billion | -KRW 16 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 0 | -KRW 13.9 billion | -KRW 13.6 billion | — |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 0 | -KRW 10 billion | -KRW 3.8 billion | — |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 0 | -KRW 9.6 billion | -KRW 8.6 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 19, 2026 | KRW 0 | -KRW 51.8 billion | -KRW 42 billion | -99.9% |
| FY2024Consolidated · Filed Mar 20, 2025 | KRW 20.9 billion | -KRW 8.3 billion | -KRW 5.7 billion | — |
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
- Year-to-date rows are cumulative from the start of the fiscal year.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 4.32%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 180 million
- Previous 20-day average 7.82%
- Net short position
- 255,864 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 2,693,467 shares
- As of Nov 13, 2026 · 12.38% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 4.32% | KRW 180 million |
| Nov 12, 2026 | 2.20% | KRW 40 million |
| Nov 11, 2026 | 3.11% | KRW 70 million |
| Nov 10, 2026 | 5.34% | KRW 120 million |
| Nov 9, 2026 | 4.33% | KRW 100 million |
| Nov 6, 2026 | 7.40% | KRW 230 million |
| Nov 5, 2026 | 9.21% | KRW 330 million |
| Nov 4, 2026 | 11.11% | KRW 340 million |
| Nov 3, 2026 | 17.19% | KRW 480 million |
| Nov 2, 2026 | 9.30% | KRW 180 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Oct 29, 2026 · Insider Ownership Report
- Results of Extraordinary General Meeting(Korean)Oct 23, 2026 · Shareholders Meeting
- Shareholders Meeting(Korean)Oct 22, 2026
- Report on Major Holdings of Shares (General Form)(Korean)Oct 21, 2026 · Major Holding Report
- Material Management Information(Korean)Sep 17, 2026
- Resolution to Convene a Shareholders Meeting (Extraordinary General Meeting)(Korean)Sep 10, 2026 · Shareholders Meeting
- Adjustment of Conversion Price of Convertible Shares (Convertible Preferred Shares)(Korean)Aug 18, 2026 · Conversion or Exercise Price Adjustment
- Adjustment of Conversion Price of Convertible Shares (Convertible Preferred Shares)(Korean)Aug 14, 2026 · Conversion or Exercise Price Adjustment
Filings with a published English version open in English; the rest link to the Korean original.
Orum Therapeutics (475830) stock information
KOSDAQ
Orum Therapeutics (475830) is listed on KOSDAQ. Its market capitalization is about KRW 320.4 billion. On trailing-twelve-month earnings the P/E ratio is 17.31, and the P/B ratio is 1.72. Return on equity is 10%. These figures are computed in-house from official filings and are reference information only.
Orum Therapeutics — frequently asked questions
- What is the P/E ratio of Orum Therapeutics (475830)?
- On a trailing-twelve-month basis, 475830 trades at a P/E ratio of 17.31. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Orum Therapeutics?
- 475830 has a market capitalization of about KRW 320.4 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.